Atossa Therapeutics details accelerated FDA strategy for (Z)-Endoxifen breast cancer drug.

Atossa Therapeutics completed a Type C meeting with the FDA to discuss regulatory strategies for advancing (Z)-endoxifen. The FDA provided feedback on potential expedited pathways for metastatic disease, neoadjuvant treatment, and breast cancer risk-reduction settings. The meeting aimed to transform breast cancer treatment and prevention.